

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Simcere Pharmaceutical Group Limited

先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2096)

VOLUNTARY ANNOUNCEMENT

THE INCLUSION OF XIANNUOXIN[®], AN ANTI-SARS-COV-2 INNOVATIVE DRUG, IN THE NEW NATIONAL REIMBURSEMENT DRUG LIST

This announcement is made by Simcere Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, on December 13, 2023, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security published the “Drugs Catalogue for the National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance (2023)” (《國家基本醫療保險、工傷保險和生育保險藥品目錄(2023年)》) (the “**New NRDL**”), pursuant to which, XIANNUOXIN[®], an innovative drug of the Group used for the treatment of adult patients infected with mild to moderate COVID-19, was officially included in the New NRDL.

On January 28, 2023, XIANNUOXIN[®] was conditionally approved for marketing by the National Medical Products Administration of China (NMPA). On February 8, 2023, XIANNUOXIN[®] was included in the temporary scope of medical insurance reimbursement. As of December 2023, XIANNUOXIN[®] has covered 32 provinces, 306 cities and over 2,500 hospitals nationwide. As the first domestic 3CL anti-SARS-CoV-2 innovative drug, the inclusion of XIANNUOXIN[®] in the New NRDL will further improve the drug accessibility and benefit more patients in China.

ABOUT XIANNUOXIN®

XIANNUOXIN® (Simnotrelvir Tablets/Ritonavir Tablets (co-packaged)) is an oral small molecule anti-SARS-CoV-2 innovative drug. Simnotrelvir targets 3CL protease which is essential for SARS-CoV-2 virus replication, and its combination with low-dose Ritonavir helps to slow down the metabolism or breakdown of Simnotrelvir in body in order to improve the antiviral effect. On November 17, 2021, the Group entered into a technology transfer contract with Shanghai Institute of Materia Medica and Wuhan Institute of Virology, Chinese Academy of Sciences, pursuant to which, the Group obtained the development, production and commercialization rights on an exclusive basis of Simnotrelvir worldwide. The results of phase II/III clinical studies show that XIANNUOXIN® can accelerate the recovery from symptoms, shorten the duration of the disease and nucleic acid conversion time, reduce viral load over 96% rapidly and significantly, and demonstrate good safety and tolerance.

ABOUT THE COMPANY

The Company is an innovation and R&D-driven pharmaceutical company and has established a “State Key Laboratory of Neurology and Oncology Drug Development”. The Company focuses on the therapeutic areas of oncology, nervous system, autoimmune and anti-infection, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of “providing today’s patients with medicines of the future”. Driven by its in-house R&D efforts and synergistic innovation, the Company has established strategic cooperation partnerships with many innovative companies and research institutes.

By order of the Board
Sincere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, December 13, 2023

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director, Mr. TANG Renhong, Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.